Epigenetic Modulation: Research Progress on Histone Acetylation Levels in Major Depressive Disorders

Meng Ye,Juan Du,Ning Liu,Ya‐Wei Qiang,Lifei Xiao,Xiao-Bing Lan,Lin Ma,Jia-Mei Yang,Jianqiang Yu,Guangyuan Lu
DOI: https://doi.org/10.1080/1061186x.2022.2125978
2022-01-01
Journal of Drug Targeting
Abstract:Depression is a serious mental illness and a prevalent condition with multiple aetiologies. The impact of the current therapeutic strategies is limited and the pathogenesis of the illness is not well understood. According to previous studies, depression onset is influenced by a variety of environmental and genetic factors, including chronic stress, aberrant changes in gene expression, and hereditary predisposition. Transcriptional regulation in eukaryotes is closely related to chromosome packing and is controlled by histone post-translational modifications. The development of new antidepressants may proceed along a new path with medications that target epigenetics. Histone deacetylase inhibitors (HDACis) are a class of compounds that interfere with the function of histone deacetylases (HDACs). This review explores the relationship between HDACs and depression and focuses on the current knowledge on their regulatory mechanism in depression and the potential therapeutic use of HDACis with antidepressant efficacy in preclinical research. Future research on inhibitors is also proposed and discussed.
What problem does this paper attempt to address?